Picoplatin

Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer

- New Progression-Free Survival Data To Be Presented at 2009 ASCO Annual Meeting Support Further Clinical Development of Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Poniard Management Team to Host Analyst an...

Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability

- Pharmacologic Data Presented at American Association for Cancer Research's 100th Annual Meeting 2009 - SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced...

Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology

- Findings Demonstrate Survival Benefit with Picoplatin as Second-Line Therapy for Small Cell Lung Cancer - SOUTH SAN FRANCISCO, Calif., April 20 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced...

Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization

SOUTH SAN FRANCISCO, Calif., March 20 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it will concentrate its cash resources on the clinical and commercial development of its late-stage oncology candid...

Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin

SOUTH SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today provided an overview of its 2009 clinical goals for development of picoplatin, its lead product candidate. Picoplat...

Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August

...motherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. picoplatin is designed to overcome platinum resistance associ... and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer ...

Poniard Pharmaceuticals to Present at Needham & Company's Cancer Therapeutics: Today & Tomorrow Conference

...emotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. picoplatin is designed to overcome platinum resistance associ...s and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer ...

Poniard Pharmaceuticals Receives Going Concern Qualification

...emotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. picoplatin is designed to overcome platinum resistance associ...s and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer ...

Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer

...Poniard well as we continue our efforts to advance picoplatin to market," said Jerry McMahon, Ph.D., chairman an...omplete enrollment in our pivotal Phase 3 trial of picoplatin in small cell lung cancer and to develop strategic...e in the Company's history," said Mr. Weaver. "The picoplatin clinical data to date demonstrates the commercial ...

Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update

...continued to make important progress in developing picoplatin as an oncology platform compound, addressing multi...k, we presented positive updated Phase 2 data with picoplatin in colorectal cancer (CRC) and hormone-refractory ...latin in lung cancer (SCLC) is on track to advance picoplatin toward commercialization in 2010," said Jerry McMa...

Picoplatin in Medical Technology

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

SOUTH SAN FRANCISCO, Calif., July 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

- New Progression-Free Survival, Disease Control and Neurotoxicity Data To Be Presented at 2009 ASCO Annual Meeting Continue to Support Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for First-Line Treatment of Colorectal Cancer - - Poniard Management Team to Host Analyst and I...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials - - Company to Hold Investor Event on Sunday, May 31 with Oncology Experts - SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today ann...

Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it has reached its enrollment target of 400 patients in the SPEAR (Study of Picoplatin Efficacy After Relapse) tria...

Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer

- Poster Presented at ASCO Annual Meeting - SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced safety and efficacy results from a previously unp...

Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer

- Phase 2 Data To Be Presented Along With Updated Phase 1 Colorectal Cancer Data at ASCO Annual Meeting - SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology,...

Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer

- Poster Presented at ASCO Annual Meeting - SOUTH SAN FRANCISCO, Calif. and CHICAGO, May 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ong...

Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting

- Safety and Efficacy Clinical Data from Prostate, Colorectal and Ovarian Cancers - - Company to Hold Investor Event on Sun., June 1 with Oncology Experts - SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD...

Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer

- Preliminary Phase 1 and 2 Data Expected at ASCO in June - SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase ...

Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit

- Final Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung Cancer Conference - SOUTH SAN FRANCISCO, Calif., April 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announce...

Picoplatin in Biological Technology

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today announced that the independent Data Monitoring Committee (DMC), after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the ...

Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer

- Safety and Tumor Response Data from Dose-Escalation Study Presented at American Association for Cancer Research's 100th Annual Meeting 2009 - SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical com...

Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting

-- Phase 1 Data from Colorectal Cancer and Oral Picoplatin Trials To Be Presented -- SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that the Company will present ...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium - SOU...

Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

- Incremental Data to be Presented at ASCO GI Symposia Continue to Support Picoplatin as Neuropathy-Sparing Alternative to Oxaliplatin in First-Line Colorectal Cancer Treatment - SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a ...

Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers

SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today announced that the Company will present data from two ongoing Phase 2 clinical trials of picoplatin at two ...

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

- Updated Preliminary Results Presented at 20th EORTC-NCI-AACR Symposium - SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced positive incremental data from it...

Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

- Updated Results Presented at 20th EORTC-NCI-AACR Symposium - SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced positive incremental data from its ongo...

Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that its lead product candidate, picoplatin, has been granted orphan medicinal product designation for the treatment o...

Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin

SOUTH SAN FRANCISCO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced an agreement with Baxter Oncology GmbH for the commercial manufacture and supply of injectable picoplatin drug product. P...